Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone.

Dutcher JP, Wilding G, Hudes GR, Stadler WM, Kim S, Tarazi JC, Rosbrook B, Rini BI. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol. 2008 May 20; 26(15_suppl):5127.

View in: PubMed

collapse authors with profiles